CONCLUSION

This chapter has examined the conceptual and practical elements of screening for compensational purposes. We have linked these issues to the committee’s adoption of a PC/AS model and we have noted some clinical and epidemiologic issues related to compensable diseases. Some of our recommendations are directed at agents that would need to amend RECA (or RESEP) legislation; others are directed at steps that HRSA can consider without statutory changes. The next chapter addresses on the remaining core elements of the RESEP program: education and outreach.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement